Phosphate binders

VFMCRP announces positive results of phase-III clinical trial of Velphoro® in China

Retrieved on: 
Friday, April 30, 2021

The study met its primary endpoint demonstrating non-inferiority versus sevelamer carbonate in the change from baseline in serum phosphorus levels at week 12.\nDr.

Key Points: 
  • The study met its primary endpoint demonstrating non-inferiority versus sevelamer carbonate in the change from baseline in serum phosphorus levels at week 12.\nDr.
  • In 2020, Velphoro\xc2\xae became a global leader by value in the calcium-free phosphate binder market2.\n1 Zhang et al.
  • Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives.
  • Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210429005950/en/\n'

New Retrospective Two-Year Study Demonstrates Velphoro® Effectiveness

Retrieved on: 
Tuesday, March 31, 2020

"Previous real world studies have shown similar results with Velphoro, but lacked a control group," said first study author Dr. Daniel Coyne, Professor of Medicine, Washington University School of Medicine St Louis.

Key Points: 
  • "Previous real world studies have shown similar results with Velphoro, but lacked a control group," said first study author Dr. Daniel Coyne, Professor of Medicine, Washington University School of Medicine St Louis.
  • "This two-year analysis addresses that problem, and shows marked improvements with Velphoro that are not achieved using other phosphorus binders."
  • Velphoro is a non-calcium, chewable, iron-based phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis.
  • Velphoro has a high phosphate-binding capacity relative to equivalent doses of other commonly prescribed phosphate binders and the iron in Velphoro is minimally absorbed.

Ardelyx Announces Positive Topline Results from Pivotal Phase 3 PHREEDOM Study Evaluating Tenapanor in CKD Patients on Dialysis

Retrieved on: 
Tuesday, December 3, 2019

Tenapanor is an investigational, first-in-class, phosphate absorption inhibitor being developed to treat hyperphosphatemia in patients with CKD on dialysis.

Key Points: 
  • Tenapanor is an investigational, first-in-class, phosphate absorption inhibitor being developed to treat hyperphosphatemia in patients with CKD on dialysis.
  • If approved, tenapanor will be the only non-binder treatment for the control of serum phosphorus in patients with CKD on dialysis.
  • Patients entering the study from the tenapanor arm with serum phosphorus levels in the normal range are followed with no medication changes.
  • In addition to the positive results of the PHREEDOM trial, the company previously reported results from its first Phase 3 monotherapy study with tenapanor in patients with CKD on dialysis, reporting that the primary endpoint was met (p=0.01).

Ardelyx Announces Presentation at Kidney Week 2019

Retrieved on: 
Wednesday, November 6, 2019

FREMONT, Calif., Nov. 6, 2019 /PRNewswire/ --Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced a late-breaking oral presentation of its recently announced AMPLIFY Phase 3 clinical data will be presented at Kidney Week 2019, the American Society of Nephrology's Annual Meeting, to be held November 5-10, 2019, in Washington D.C.

Key Points: 
  • FREMONT, Calif., Nov. 6, 2019 /PRNewswire/ --Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced a late-breaking oral presentation of its recently announced AMPLIFY Phase 3 clinical data will be presented at Kidney Week 2019, the American Society of Nephrology's Annual Meeting, to be held November 5-10, 2019, in Washington D.C.
  • Details for the presentation are as follows:
    Title:Efficacy of tenapanor in combination with phosphate binders in patients with CKD on dialysis with uncontrolled hyperphosphatemia on phosphate binders alone.
  • Presenters:Pablo E. Pergola, Renal Associates, P.A., San Antonio, TX, USA, David P. Rosenbaum, Ardelyx, Inc., Fremont, CA, USA, Yang Yang, Ardelyx, Inc., Fremont, CA, USA, and Glenn Chertow, Division of Nephrology, Stanford University School of Medicine, Stanford, CA, USA
    For more information about Kidney Week 2019, visit https://www.asn-online.org/education/kidneyweek/ .
  • To efficiently bring its treatments to market, Ardelyx is pursuing strategic collaborations for tenapanor for IBS-C and hyperphosphatemia in certain territories.

Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment

Retrieved on: 
Tuesday, September 3, 2019

Tenapanor is an investigational, first-in-class, small molecule, non-binder, phosphate absorption inhibitor being developed to treat hyperphosphatemia in patients with CKD on dialysis.

Key Points: 
  • Tenapanor is an investigational, first-in-class, small molecule, non-binder, phosphate absorption inhibitor being developed to treat hyperphosphatemia in patients with CKD on dialysis.
  • The AMPLIFY study results provide convincing evidence that controlling hyperphosphatemia will soon be within our reach."
  • We look forward to reporting results from our second Phase 3 monotherapy study, PHREEDOM, in the fourth quarter of this year.
  • The promising results from AMPLIFY bring us one step closer to providing this important medicine to patients with CKD on dialysis."

US Nephrologists Report Few Gains in the CKD-MBD Market for Akebia's Auryxia, Amgen's Parsabiv, and Opko's Rayaldee Despite Reports That They Would Like to Expand Use of All Three Products

Retrieved on: 
Tuesday, June 25, 2019

Use of sevelamer (Renvela/sevelamer generics) has held steady during this time, although nephrologists do report projected offsets in favor of Auryxia and Velphoro in the near future.

Key Points: 
  • Use of sevelamer (Renvela/sevelamer generics) has held steady during this time, although nephrologists do report projected offsets in favor of Auryxia and Velphoro in the near future.
  • Spherix quarterly updates for the renal anemia market are scheduled to be released this week.
  • Subscriptions to the service are available for the following markets: Bone and Mineral Metabolism, Renal Anemia, Hyperkalemia, and Polycystic Kidney Disease.
  • All company, brand or product names in this document are trademarks of their respective holders.

Global Alumina Trihydrate Markets 2019-2024: Opportunities and Future Trends in the Increasing Usage in Batteries and Chemicals

Retrieved on: 
Monday, April 29, 2019

The market for alumina trihydrate is anticipated to register a CAGR of 5.63% during the forecast period 2019 and 2024.

Key Points: 
  • The market for alumina trihydrate is anticipated to register a CAGR of 5.63% during the forecast period 2019 and 2024.
  • Increasing demand for plastics from various end-user industries are expected to drive the demand for the market during the forecast period.
  • Availability of some non-toxic substitutes such as Magnesium Hydroxide and Calcium Carbonate is likely to hinder the market's growth.
  • Increasing usage of alumina trihydrate in the new applications such as batteries, chemicals, etc., is projected to act as an opportunity for the market in the future.

Vifor Pharma and Akebia Therapeutics Announce Expansion of Licence Agreement

Retrieved on: 
Tuesday, April 9, 2019

Under the terms of the agreement signed in May 2017, Akebia granted Vifor Pharma a licence to sell vadadustat to Fresenius Medical Care North America for use solely within its dialysis clinics in the U.S., subject to FDA approval.

Key Points: 
  • Under the terms of the agreement signed in May 2017, Akebia granted Vifor Pharma a licence to sell vadadustat to Fresenius Medical Care North America for use solely within its dialysis clinics in the U.S., subject to FDA approval.
  • Vifor Pharma and Akebia believe that vadadustat has the potential to set a new oral standard of care for patients with anaemia due to CKD.
  • The Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma, a joint company with Fresenius Medical Care; Relypsa; and OM Pharma.
  • Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on the development and commercialisation of therapeutics for patients with kidney disease.

Velphoro® Doubles Percentage of Patients Reaching Target Serum Phosphorous Levels in New Study Published in Journal of Renal Nutrition

Retrieved on: 
Monday, January 28, 2019

High serum phosphorous levels, or hyperphospatemia, have previously been associated with increased cardiovascular disease and mortality.

Key Points: 
  • High serum phosphorous levels, or hyperphospatemia, have previously been associated with increased cardiovascular disease and mortality.
  • Oral phosphate binders, in combination with dialysis and dietary restriction, have been shown to effectively lower elevated phosphorus levels.
  • Sucroferric oxyhydroxide (Velphoro) is a non-calcium, chewable, iron-based phosphate binder indicated for the treatment of hyperphosphatemia in dialysis patients.
  • For more details of the study, read the manuscript online in the Journal of Renal Nutrition .

Fresenius Medical Care North America Launches Corporate Charitable Foundation

Retrieved on: 
Wednesday, April 25, 2018

WALTHAM, Mass., April 25, 2018 /PRNewswire/ -- Fresenius Medical Care North America (FMCNA) , the leading provider of kidney care products and services, today announced the launch of the Fresenius Medical Care Foundation, a nonprofit created to address the environmental, social and economic conditions that increase the risk for chronic kidney disease (CKD).

Key Points: 
  • WALTHAM, Mass., April 25, 2018 /PRNewswire/ -- Fresenius Medical Care North America (FMCNA) , the leading provider of kidney care products and services, today announced the launch of the Fresenius Medical Care Foundation, a nonprofit created to address the environmental, social and economic conditions that increase the risk for chronic kidney disease (CKD).
  • FMCNA has pledged to match donations from its employees, medical staff and other individuals up to$1 million to fund the Foundation in its inaugural year.
  • Fresenius Medical Care North America is the premier health care company focused on providing the highest quality care to people with renal and other chronic conditions.
  • Through its industry-leading network of dialysis facilities, outpatient cardiac and vascular labs, and urgent care centers, as well as the country's largest practice of hospitalist and post-acute providers, Fresenius Medical Care North America provides coordinated health care services at pivotal care points for hundreds of thousands of chronically ill customers throughout the continent.